A new study published in Metabolites reveals that Bimuno® galacto-oligosaccharides (GOS) deliver a significant prebiotic effect at doses as low as 380 mg of active GOS—far below other effective prebiotic doses (1.5 - 30 g per day). Using the advanced SIFR® ex vivo technology from Cryptobiotix, a CRO and pioneer in preclinical gastrointestinal research with expertise in gut health and microbiome research based in Ghent, Belgium, the researchers demonstrated that ultra-low doses of Bimuno® GOS significantly increased beneficial Bifidobacteriaceae, boosted production of short-chain fatty acids (SCFAs) without significantly increasing gas production, and lowered intestinal / gut pH. 

As the exclusive North American distributor of Bimuno®, Stratum Nutrition® sees this breakthrough as a pivotal moment for the prebiotic category. “The North American market is hungry for scientifically proven prebiotic solutions that can be delivered in convenient formats,” said David Hoover, Marketing Manager at Stratum Nutrition. “These findings strengthen Bimuno’s position as a leader in gut health innovation and create exciting opportunities for our brand partners to differentiate with true science-backed benefits.” 

“This study shows that meaningful prebiotic effects can be achieved at ultra-low doses,” added Dr. Lucien Harthoorn, R&D Director of Clasado Biosciences. “By demonstrating efficacy from just 380 mg of active GOS per day, we open the door to capsule and tablet formats that are more convenient for consumers, giving formulators far greater flexibility than ever before.” 

The results showed that SCFA production rose significantly from the 380 mg dose of active GOS. The ultra-low dose of Bimuno® GOS also promoted propionate production by Phocaeicola vulgatus, a strain of interest for its beneficial metabolic activity. Additional microbes tied to gut and immune health were also enriched, even at the ultra-low dose. 

The ability of Bimuno® GOS to exert a significant prebiotic effect at ultra-low doses opens the door for a new generation of functional products, particularly in beverages and everyday foods where delivering meaningful doses has been a challenge. With Bimuno® GOS, formulators can incorporate effective prebiotic support directly into these formats, enabling consumers to access gut health benefits through products that seamlessly fit into their daily routines. 

About Clasado Biosciences 

Clasado Biosciences is a global leader in the development of prebiotic ingredients, dedicated to advancing gut health through science-led innovation. Headquartered in the UK, Clasado develops and commercializes evidence-based solutions for the health and nutrition sectors worldwide. The company’s flagship ingredient, Bimuno®, is one of the most extensively researched prebiotics, with proven applications across dietary supplements, functional foods, medical nutrition, and beyond. 

About Stratum Nutrition® 

Stratum Nutrition® is the exclusive North American distributor for Bimuno®, partnering with Clasado Biosciences to bring this cutting-edge prebiotic to brands across the U.S. and Canada. Stratum delivers proven functional ingredients to the dietary supplement and functional food industries, offering end-to-end support and expertise that help brand partners bring science-backed innovations to market successfully.